ArticleOphthalmology and therapy2025

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF.

H Mhmud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.